Betterlife Pharma Inc. · CSE:BETR

Betterlife Pharma — Investor Presentation (December 2021)

23 slides from Betterlife Pharma's investor presentation, December 2021

  1. Slide 1: Life Sciences Company with an Evolving Portfolio of Novel Psychedelic and Anti-Viral Drugs

    Life Sciences Company with an Evolving Portfolio of Novel Psychedelic and Anti-Viral Drugs December 2021 BETRF : OTCBB BETR : CSE

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. BetterLi

  3. Slide 3: Highlights

    Highlights MENTAL HEALTH Second Generation, Non-Hallucinogenic Psychedelic Drugs  Patient friendly answer to mental health’s unmet needs  No scheduled drug restrictions and faster development RESPIRATORY HEALTH Novel Anti-Viral Drugs for Treatment and Potential Prevention of Pandemics  Effective

  4. Slide 4: Three Compelling & Differentiated Assets

    Three Compelling & Differentiated Assets 4 Second Generation (non-hallucinogenic) Psychedelics BETR-001 (formerly TD-0148A): 2-bromo-LSD (oral)  Indication: Major depressive disorder (MDD) & Cluster Headaches  IND filing projected Q3 2022  IP: Two manufacturing patents that eliminate controlled s

  5. Slide 5: BETR-001

    BETR-001 BETR-001 (formerly TD-0148A) Non-Hallucinogenic LSD 2-bromo-LSD Potential Treatment of Major Depressive Disorders and Other Neuro-Psychiatric Disorders

  6. Slide 6: BETR-001 (formerly TD-0148A): 2-bromo-LSD – Background

    BETR-001 (formerly TD-0148A): 2-bromo-LSD – Background BOL-148 (2-bromo-LSD) o BOL-148 is not a controlled substance, but due to its synthesis from LSD, its manufacturing is regulated as for LSD o Was originally synthesized by Albert Hofmann, the chemist who invented LSD o BOL-148 shown to be non-ha

  7. Slide 7: The BETR-001 Advantage: Benefits of LSD without the hallucinations + Not a controlled substance

    The BETR-001 (formerly TD-0148A) Advantage: Benefits of LSD without the hallucinations + Not a controlled substance The Achilles Heel of Psychedelics 1 Two main issues which arise from their “hallucinogenic” properties: 1. Administration must be performed in special clinics with close monitoring by

  8. Slide 8: BETR-001 IP: Proprietary Synthesis (Issued) and Method of Use (Pending)

    BETR-001 (formerly TD-0148A) IP: Issued IP: Synthesis Proprietary Synthesis (Issued) and Method BetterLife synthesis patent for 2-Bromo-LSD eliminates regulatory hurdles. BETR-001 is an unregulated, of Use (Pending) unscheduled molecule, with no legal barriers to surmount. Filed IP (pending): Method

  9. Slide 9: BETR-001: A Significant Market Opportunity

    BETR-001 (formerly TD-0148A): A Significant Market 9 Opportunity Depression and Other Neuro-Psychiatric Disorders Market Share, by Indication 1 o The global depression drugs market reached US$ 12.41 Billion in 2019. 2 o According to the WHO, depression is one of the leading causes of disability and

  10. Slide 10: BETR-001 Development Plan Projections

    BETR-001 (formerly TD-0148A) Development Plan Projections Drug Delivery Indication Current Status IND Phase 1 1 Phase 2 2 Ph 1 in Healthy Oral Major Depressive Preclinical Ph 2 in MDD BETR-001 Filing projected Subjects (capsules) Disorder IND-enabling studies 2023 Q3 2022 Projected start Q4 GMP Manu

  11. Slide 11: BETR-002

    BETR-002 BETR-002 (formerly TD-010) Dihydrohonokiol-B (DHH-B) Potential Treatment of Anxiety and other Neuro- Psychiatric Disorders

  12. Slide 12: BETR-002: Dihydrohonokiol (DHH-B) – The Background

    BETR-002 (formerly TD-010): Dihydrohonokiol (DHH-B) – The Background Honokiol (the parent of DHH-B) o Magnolia bark extracts have been used in traditional Chinese medicines for centuries as anxiolytic (anti- anxiety medication) o Several animal studies on safety and anxiolytic efficacy of honokiol/m

  13. Slide 13: BETR-002 IP: Proprietary Formulation & Method of Use (Pending)

    BETR-002 (formerly TD-010) IP: Filed IP (pending): Formulation Proprietary Formulation & Method of Use BetterLife’s patented formulation improves bioavailability. Formulations covered include oral capsules, tablets, sub- (Pending) lingual etc delivery. Filed IP (pending): Method of Use Filing covers

  14. Slide 14: BETR-002: A Significant Market Opportunity

    BETR-002 (formerly TD-010): A Significant Market Opportunity 14 o Benzodiazepines market was valued at US$ 3.48 Billion in 2019 and is projected to reach US$ 4.15 Billion by 2027, growing at a CAGR of 2.25% from 2020 to 2027. o Rise in prevalence of anxiety and seizures is a major driver of the glob

  15. Slide 15: BETR-002 Development Plan Projections

    BETR-002 (formerly TD-010) Development Plan Projections 15 Drug Delivery Indication Current Status IND Phase 1 Phase 2 Ph 1 in healthy subjects OR Oral Benzodiazepine Filing projected BETR-002 Preclinical Ph 1-2 in patients 1 (capsules) Dependency H1 2023 IND-enabling studies Projected start H1 2023

  16. Slide 16: AP-003 Interferon alpha-2b (IFNα2b)

    AP-003 AP-003 Interferon alpha-2b (IFN⍺2b) Inhalation Potential Treatment & Prophylaxis of COVID-19

  17. Slide 17: AP-003: Unique Market Position and Opportunity

    17 AP-003: Unique Market Position and Opportunity o AP-003 is being developed as a novel interferon alpha-2b (IFN⍺2b) inhalation formulation o U of Texas, showed evidence of a direct anti-viral effect of interferon alpha against novel coronavirus in vitro. The study demonstrated around 10,000 fold r

  18. Slide 18: AP-003 Patent Pending Application Covers Composition, Formulation and Treatment

    AP-003 Patent Pending Application Covers Composition Formulation Composition, Formulation and Treatment • AP-003 is manufactured from a • Patent pending proprietary AP- 003 formulation improves stability novel IFNa2b recombinant clone. of the IFNa2b and is adapted to The IFNa2b is “isoform” free. in

  19. Slide 19: AP-003 Development Plan Projections

    AP-003 Development Plan Projections Manufacturing / Drug Delivery Indication Pre-Clinical / IND Phase 1 Phase 2 IND enabling studies Inhalation Treatment Filing projected Ph 1-2 in US 2 AP-003 + (nebulizer) Early Stage Covid-191 Q3 2022 Start Q4 2022 PoC Chilean Ph 1-2 Study (discussed below) o In 2

  20. Slide 20: Leadership

    Leadership Leadership

  21. Slide 21: Leadership Team

    Leadership Team Management Advisors Ahmad Doroudian, PhD Founder, CEO Jeff Fellows, Regulatory Affairs 21 25+ years experience in finance, M&A, Founder of Merus Labs (NASDAQ: MSLI) Hooshmand Sheshbaradaran, PhD, Chief Operating Officer Thomas P. Laughren, M.D. Psychiatry 30+ years senior pharma exec

  22. Slide 22: Share Capital

    Share Capital Issued and Outstanding Exercise Price Common shares 85,191,241 N/A Restricted and performance stock units 35,000 N/A Stock options 2,150,000 C$0.27 – C$0.77 200,000 C$1.33 – C$1.80 60,000 C$2.40 – C$2.60 Warrants 238,095 C$0.27 23,316,250 C$0.50 6,386,298 C$0.60 452,595 C$1.21 – C$1.88

  23. Slide 23: Thank You

    BLOCKCHAIN Thank You Contact: CEO: Ahmad Doroudian, Ph.D BetterLife Pharma Inc. 300 - 1275 West 6th Avenue Vancouver, BC V6H 1A6 Canada. Tel: 604 221-0595 Ahmad.Doroudian@blifepharma.com

BetterLife Pharma — Investor Presentation (December 2021) on 6ix